CompletedPhase 2NCT05957978

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Drugs for Neglected Diseases
Principal Investigator
Mezgebu Silamsaw, Dr
University of Gondar, Ethiopia
Intervention
LXE408(drug)
Enrollment
52 target
Eligibility
18-44 years · All sexes
Timeline
2024 – 2025

Study locations (1)

Collaborators

Novartis Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05957978 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials